sonanano.comCrawled Nov 8, 2026
Being developed to provide early detection at low cost without the need for test-and-slaughter.
Available for Mac, Windows, Chrome, and iOS.
Sona’s CTAB-free gold nanorods were tested in a first-in-human clinical study, achieving an 80% overall response rate in 10 immunotherapy-resistant late-stage melanoma patients. Dalhousie University confirmed immune activity in patient samples.
Sona is using its biocompatible GNRs in the development of Targeted Hyperthermia Therapy.
The company recommends placing orders through its website for faster processing and turnaround, accepting Purchase Orders via email, fax, or mail on company letterhead. Custom product orders must be placed by email or phone.
The page allows users to review their selection and request a pricing quote without needing an account or payment.
Inventor of gold nanorods Peter C. and Gretchen Miller Markunas Professor of Chemistry at the University of Illinois at UrbanaChampaign (UIUC).
Past-president of Sanofi Pasteur Limited. Co-Chair of the Government of Canada’s COVID-19 Vaccine Task Force. Director of OncoQuest Pharmaceuticals, Biome Grow, and the Gairdner Foundation. MBA, FCPA.
Business and commercial operations oversight. Strategy consultant and corporate director. 15 years public company experience in strategy, IR and corporate development. MBA from INSEAD and BBA (Hons) from St. FXU.
From an idea formed in a small university laboratory the Sona story is one of people, passion, and perseverance.
Sona Nanotech Inc. develops Targeted Hyperthermia Therapy (THT), a treatment platform for solid tumors using its CTAB-free gold nanorod technology. The company completed a first-in-human study showing responses in 8 of 10 immunotherapy-resistant melanoma patients.
Sona Nanotech appoints **Dr. Kulbir Singh** as its new **Chief Technology Officer**. The company also grants **2.375 million incentive stock options** annually under its Stock Option Plan, with **2.07 million** allocated to directors and officers. Each option is exercisable into one common share at a set price.
Sona Nanotech secures **$2.53 million** in an oversubscribed private placement to advance its **Targeted Hyperthermia Therapy** for oncology treatment. The Halifax-based company uses the funds to expand development of its precision cancer treatment technology. The round reflects investor confidence in its potential to improve therapeutic outcomes through localized heat-based tumor destruction.
Sona Nanotech raises **$2.5 million** through an over-subscribed private placement, issuing **8.4 million shares** at **$0.30 each**. The financing follows an earlier announcement on **July 31, 2026**, with all securities subject to a **four-month hold period**. The company trades on the **CSE (SONA)** and **OTCQB (SNANF)**.
Sona Nanotech advances its melanoma treatment pipeline by initiating two clinical studies combining its **Thermally Activated Hyperthermic Therapy (THT)** with other therapies. The trials aim to evaluate safety and efficacy in patients with advanced or unresectable melanoma. The company leverages its proprietary nanotechnology platform to enhance localized tumor heating as part of the combination approach.
Sona Nanotech presents early-stage findings for its cancer therapy at major oncology conferences. The company highlights preclinical data demonstrating targeted drug delivery using nanotechnology. Researchers focus on improving treatment efficacy while minimizing side effects for patients.